Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

6533b858fe1ef96bd12b628c

RESEARCH PRODUCT

Dynamic contrast-enhanced MRI parameters as biomarkers for the effect of vatalanib in patients with non-small-cell lung cancer.

Benjamin Besse B. Fischer Mark A. Horsfield Valérie Gounant Thomas Gauler Heiko Krissel Bruno Morgan Wilfried Eberhardt Jean-charles Soria Daniel C. Christoph Daniel C. Christoph J. Stattaus Antoine Khalil D. Laurent Felix Nensa Katja Seng

subject

Male Cancer Research medicine.medical_specialty Vatalanib Drug-Related Side Effects and Adverse Reactions Pyridines Medizin Contrast Media Angiogenesis Inhibitors Stable Disease Text mining Carcinoma Non-Small-Cell Lung medicine Humans In patient Lung cancer Aged Neoplasm Staging Clinical Trials as Topic business.industry General Medicine Middle Aged medicine.disease Magnetic Resonance Imaging Radiography Oncology Response Evaluation Criteria in Solid Tumors Dynamic contrast-enhanced MRI Drug Evaluation Phthalazines Female Radiology Nuclear medicine business Progressive disease Biomarkers

description

ABSTRACT: Aims: To assess the utility of dynamic contrast-enhanced MRI parameters in the demonstration of early antiangiogenic effects and as prognostic biomarkers in second-line treatment of advanced-stage non-small-cell lung cancer with vatalanib. Patients & methods: The transfer constant (Ktrans) and the initial area under the contrast concentration–time curve at 60 s (AUC60) were assessed in 46 patients. Changes were compared with response evaluation from computed tomography imaging and Response Evaluation Criteria In Solid Tumors guidelines. Results: Statistically significant mean reductions in Ktrans (38.4%; p < 0.0001) and AUC60 (24.9%; p < 0.0001) were found at day 2. After 12 weeks, 16 patients (35%) demonstrated stable disease and 30 (65%) demonstrated progressive disease. No statistically significant differences in day 2 Ktrans and AUC60 reductions between stable disease and progressive disease patients were found. Conclusion: Dynamic contrast-enhanced MRI can demonstrate a statistically significant reduction in vascular parameters of non-small-cell lung cancer, but does not predict patient outcome.

year	journal	country	edition	language
2014-05-07	Future oncology (London, England)

10.2217/fon.13.248 https://pubmed.ncbi.nlm.nih.gov/24799063